Literature DB >> 20659770

Optimal cutoff point of the Hamilton Rating Scale for Depression according to normal levels of social and occupational functioning.

Irene Romera1, Víctor Pérez, José Manuel Menchón, Pepa Polavieja, Inmaculada Gilaberte.   

Abstract

The main goal in the treatment of major depressive disorder (MDD) is to achieve remission, defined as the resolution of symptoms and the return to normal levels of functionality. However, the clinical assessment of remission is usually merely based on scores of symptomatic rating scales. One of the most widely used scales to measure remission is the HAM-D(17), in which remission is defined as a score ≤ 7. Nevertheless, several studies have shown that this cutoff could be too high when also functioning is considered. This is a post-hoc analysis of a 6-month prospective study, performed over a sample of 292 Spanish patients with MDD, in order to find the optimal cutoff in the HAM-D(17) scale, considering normal levels of functionality, evaluated by the SOFAS; by means of plotting Receiver Operating Characteristics (ROC) curves. Our results show that a score of ≤ 5 maximized both sensitivity and specificity for identifying normal levels of functionality with respect to other scores, and thus agree with previous works, which suggest that a cutoff ≤ 7 might be too high to consider remission in patients with MDD, when normal levels of functioning are taken into account.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20659770     DOI: 10.1016/j.psychres.2010.06.023

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  19 in total

1.  A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.

Authors:  Frances R Levin; John Mariani; Daniel J Brooks; Martina Pavlicova; Edward V Nunes; Vito Agosti; Adam Bisaga; Maria A Sullivan; Kenneth M Carpenter
Journal:  Addiction       Date:  2013-03-21       Impact factor: 6.526

2.  [Costs and associated factors with optimal and suboptimal responses to the treatment of major depressive disorder].

Authors:  Antoni Sicras-Mainar; Jorge Mauriño; Luis Cordero; Milagrosa Blanca-Tamayo; Ruth Navarro-Artieda
Journal:  Aten Primaria       Date:  2012-07-11       Impact factor: 1.137

3.  Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine.

Authors:  Timothy E Wilens; Lenard A Adler; Yoko Tanaka; Feng Xiao; Deborah N D'Souza; Stephen W Gutkin; Himanshu P Upadhyaya
Journal:  Curr Med Res Opin       Date:  2011-10-27       Impact factor: 2.580

4.  Depression and episodic memory across the adult lifespan: A meta-analytic review.

Authors:  Taylor A James; Samuel Weiss-Cowie; Zachary Hopton; Paul Verhaeghen; Vonetta M Dotson; Audrey Duarte
Journal:  Psychol Bull       Date:  2021-11       Impact factor: 23.027

5.  Avoidant Coping and Poor Sleep Efficiency in Dementia Caregivers.

Authors:  Briana J Taylor; Leah A Irish; Lynn M Martire; Greg J Siegle; Robert T Krafty; Richard Schulz; Martica H Hall
Journal:  Psychosom Med       Date:  2015 Nov-Dec       Impact factor: 4.312

6.  Reduced default mode network suppression during a working memory task in remitted major depression.

Authors:  Lucie Bartova; Bernhard M Meyer; Kersten Diers; Ulrich Rabl; Christian Scharinger; Ana Popovic; Gerald Pail; Klaudius Kalcher; Roland N Boubela; Julia Huemer; Dominik Mandorfer; Christian Windischberger; Harald H Sitte; Siegfried Kasper; Nicole Praschak-Rieder; Ewald Moser; Burkhard Brocke; Lukas Pezawas
Journal:  J Psychiatr Res       Date:  2015-03-06       Impact factor: 4.791

7.  From Randomized Controlled Trials of Antidepressant Drugs to the Meta-Analytic Synthesis of Evidence: Methodological Aspects Lead to Discrepant Findings.

Authors:  Konstantinos N Fountoulakis; Roger S McIntyre; André F Carvalho
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

8.  Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis.

Authors:  Irene Romera; Víctor Pérez; Antonio Ciudad; Luis Caballero; Miguel Roca; Pepa Polavieja; Inmaculada Gilaberte
Journal:  BMC Psychiatry       Date:  2013-02-11       Impact factor: 3.630

9.  Assessment of pharmacological strategies for management of major depressive disorder and their costs after an inadequate response to first-line antidepressant treatment in primary care.

Authors:  Antoni Sicras-Mainar; Jorge Maurino; Luis Cordero; Milagrosa Blanca-Tamayo; Ruth Navarro-Artieda
Journal:  Ann Gen Psychiatry       Date:  2012-08-03       Impact factor: 3.455

10.  Approaches to psychiatric nosology: A viewpoint.

Authors:  Ajit Avasthi; Siddharth Sarkar; Sandeep Grover
Journal:  Indian J Psychiatry       Date:  2014-07       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.